We are very happy to confirm that we finally have finding from the NIHR and MRC to go ahead with the Metformin in Li Fraumeni Syndrome (MILI) trial that we’ve discussed many times over the last few years. This is significant, not just for people with LFS, but for potentially for other groups at high-risk of cancer. We’ll have more information coming up – but for now here’s the exclusive story from today’s Daily Express.
